Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...

That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab), which inhibit B cells across the board, leaving patients prone to infections and other side ...

That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab) that inhibit B cells across the board, leaving patients prone to infections and other side ...